New Content  edit
Get The App!

Loading the player...
Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Dr. David Ross Camidge, MD, PhD, University of Colorado Denver School of Medicine, discusses the use of Ceritinib and other second generation ALK inhibitors for acquired resistance in ALK-positive NSCLC, filmed at IASLC 2015.